Does Rallies show 13F holders for MIRM?

Yes. Rallies tracks hedge fund and 13F ownership data for MIRM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MIRM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MIRM. It does not provide personalized investment advice.

MIRM (Mirum Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Mirum Pharmaceuticals, Inc. Common Stock (MIRM) is a publicly traded Healthcare sector company. As of May 21, 2026, MIRM trades at $96.95 with a market cap of $5.82B and a P/E ratio of -7.07. MIRM moved +1.44% today. Year to date, MIRM is +28.31%; over the trailing twelve months it is +113.83%. Its 52-week range spans $36.88 to $114.99. Analyst consensus is strong buy with an average price target of $146.00. Rallies surfaces MIRM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MIRM stock?

Hedge funds tracked by Rallies that own MIRM include Panagora Asset, Polen Capital, Centerbook Partners, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mirum Pharmaceuticals, Inc. Common Stock.

MIRM Key Metrics

Key financial metrics for MIRM
Metric	Value
Price	$96.95
Market Cap	$5.82B
P/E Ratio	-7.07
EPS	$-13.61
Dividend Yield	0.00%
52-Week High	$114.99
52-Week Low	$36.88
Volume	465
Avg Volume	0
Revenue (TTM)	$569.61M
Net Income	$-798.84M
Gross Margin	0.00%

Top Hedge Funds Holding MIRM

Panagora Asset holds 129.11K shares of MIRM, changed +0.00% as of Mar 31, 2026.
Polen Capital holds 20.53K shares of MIRM, changed +53.68% as of Mar 31, 2026.
Centerbook Partners holds 19.70K shares of MIRM, changed -56.57% as of Mar 31, 2026.
Mangrove Partners holds 9.92K shares of MIRM, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 3.00K shares of MIRM, changed +0.00% as of Mar 31, 2026.

Latest MIRM News

Mirum prices $600M 2032 convertible notes to refinance 2029 converts — May 13, 2026
Mirum rises as volixibat Phase 2b VISTAS win keeps biotech bid alive — May 6, 2026
Mirum Pharmaceuticals’ Volixibat Trial Success Spurs $140 Price Target, 9.6% Share Jump — May 5, 2026
Mirum dips despite VISTAS volixibat Phase 2b win; investors digest details — May 4, 2026
Mirum jumps as analysts lift targets ahead of multiple 2026 trial catalysts — Apr 30, 2026

Recent MIRM Insider Trades

Ramasastry Saira sold 2.00K (~$218.94K) on May 15, 2026.
Ramasastry Saira sold 2.00K (~$193.80K) on Apr 15, 2026.
BJERKHOLT ERIC sold 7.29K (~$670.24K) on Mar 16, 2026.

MIRM Analyst Consensus

11 analysts cover MIRM: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $146.00.

Common questions about MIRM

Who owns MIRM stock?: Hedge funds tracked by Rallies that own MIRM include Panagora Asset, Polen Capital, Centerbook Partners, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mirum Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for MIRM?: Yes. Rallies tracks hedge fund and 13F ownership data for MIRM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MIRM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MIRM. It does not provide personalized investment advice.